Archives for December, 2020

Dr. Howard Hassman Interviewed on The Price of Business Show

Howard Hassman, D.O., AOBFP discussed the formation of Apex Innovative Sciences, the COVID-19 vaccine studies conducted by Hassman Research Institute and CNS Research, and the use of psychedelics to treat a variety of disorders with Kevin Price, Host of The Price of Business Show. Listen to the interview in its entirety.

Read More

Neurana Pharmaceuticals Announces Positive Top-Line Results from Tolperisone Phase 1 CNS Effects Study Conducted by Apex Sites

Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced positive top-line results from the Phase 1 central nervous effects (CNS) clinical study of tolperisone. The study, utilizing a validated driving test, confirmed that tolperisone does not impair driving performance. In addition, tolperisone does not appear to cause sleepiness, a side…

Read More

Apex Innovative Sciences Pioneers Continuity Strategy in Clinical Site Services During COVID-19

  Marlton, N.J. and Garden Grove, Calif., Dec. 2, 2020 /PRNewswire/ — Since the emergence of the COVID-19 global pandemic, Apex Innovative Sciences (Apex) has distinguished itself as a leader in clinical trial continuity strategies. On the heels of FDA and CDC guidance in March 2020, Apex immediately instituted its COVID-19 Risk Mitigation and Response…

Read More

Apex Publishes PCRS Placebo Mitigation Data

Apex Innovative Sciences has taken a leadership role in the industry with respect to researching strategies for managing the placebo and nocebo effects. A significant contribution toward this purpose is the development of the copyrighted Placebo-Control Reminder Script (PCRS) and its associated Daily No Expectation Reminder Magnet and Banner. The PCRS educates and reminds study…

Read More

Dr. Michael Hassman Discusses COVID-19 Vaccine Trial on New Jersey News Network

Dr. Michael Hassman, Medical Director and Principal Investigator at Hassman Research Institute, was featured on Larry Mendte’s “Jersey Matters” news segment. He discussed COVID-19 research, including HRI’s currently enrolling COVID-19 Vaccine Trial. Check out the interview.

Read More